NRX Pharmaceuticals, Inc. Stock-Based Compensation
NRX Pharmaceuticals, Inc. (NRXP) reported Stock-Based Compensation of $290.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $139.00K, a 107.46% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $151.00K, a 1158.33% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $81.00K, a 88.37% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $68.00K, a 34.62% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $228.00K, a 53.09% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $486.00K, a 25.58% increase from fiscal 2023.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $387.00K, a 89.33% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.63M, a 53.40% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $290.00K 10-Q · filed 2026-08-14 | $371.00K derived: sum of 3 quarters · filed 2026-08-14 | $439.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $151.00K 10-Q · filed 2026-05-15 | $232.00K derived: sum of 2 quarters · filed 2026-05-15 | $300.00K derived: sum of 3 quarters · filed 2026-05-15 | $367.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $149.00K derived: sum of 2 quarters · filed 2026-03-23 | $216.00K derived: sum of 3 quarters · filed 2026-08-14 | $228.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $135.00K derived: sum of 2 quarters · filed 2026-08-14 | $147.00K 10-Q · filed 2025-11-14 | $190.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $79.00K 10-Q · filed 2026-08-14 | $122.00K derived: sum of 3 quarters · filed 2026-08-14 | $226.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $12.00K 10-Q · filed 2026-05-15 | $55.00K derived: sum of 2 quarters · filed 2026-05-15 | $159.00K derived: sum of 3 quarters · filed 2026-05-15 | $256.00K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $147.00K derived: sum of 2 quarters · filed 2026-03-23 | $244.00K derived: sum of 3 quarters · filed 2026-03-23 | $486.00K 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $201.00K derived: sum of 2 quarters · filed 2025-11-14 | $443.00K 10-Q · filed 2025-11-14 | -$760.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $339.00K 10-Q · filed 2025-08-18 | -$864.00K derived: sum of 3 quarters · filed 2025-08-18 | -$513.00K derived: sum of 4 quarters · filed 2025-08-18 | ||
| 2024-03-31 | $242.00K 10-Q · filed 2025-05-15 | -$961.00K derived: sum of 2 quarters · filed 2025-05-15 | -$610.00K derived: sum of 3 quarters · filed 2025-05-15 | -$66.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$852.00K derived: sum of 2 quarters · filed 2025-03-14 | -$308.00K derived: sum of 3 quarters · filed 2025-03-14 | $387.00K 10-K · filed 2025-03-14 | ||
| 2023-09-30 | $351.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $895.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.59M 10-Q · filed 2024-11-14 | $2.36M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.24M 10-Q · filed 2024-08-14 | $2.00M derived: sum of 3 quarters · filed 2024-08-14 | $2.55M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $695.00K 10-Q · filed 2024-05-14 | $1.46M derived: sum of 2 quarters · filed 2024-05-14 | $2.00M derived: sum of 3 quarters · filed 2024-05-14 | $2.99M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.31M derived: sum of 2 quarters · filed 2024-03-29 | $2.29M derived: sum of 3 quarters · filed 2024-03-29 | $3.63M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $541.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.53M derived: sum of 2 quarters · filed 2023-11-14 | $2.86M 10-Q · filed 2023-11-14 | $4.43M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $987.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.32M 10-Q · filed 2023-08-14 | $3.89M derived: sum of 3 quarters · filed 2023-08-14 | $5.45M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-15 | $2.90M derived: sum of 2 quarters · filed 2023-05-15 | $4.46M derived: sum of 3 quarters · filed 2023-05-15 | $8.75M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.13M derived: sum of 2 quarters · filed 2023-03-31 | $7.41M derived: sum of 3 quarters · filed 2023-03-31 | $7.79M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $5.84M derived: sum of 2 quarters · filed 2022-11-14 | $6.21M 10-Q · filed 2022-11-14 | $6.21M 10-Q · filed 2021-11-15 | $6.57M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $4.66M 10-Q · filed 2022-08-15 | $4.66M 10-Q · filed 2021-08-16 | $5.01M derived: sum of 3 quarters · filed 2022-08-15 | $5.20M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $372.00K 10-Q · filed 2022-05-16 | $728.98K derived: sum of 2 quarters · filed 2022-05-16 | $919.73K derived: sum of 3 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $356.98K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $547.73K derived: sum of 2 quarters · filed 2022-08-12 | $730.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $190.75K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $373.02K 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | $182.27K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |